top of page
spyglass_IOL_eluting.jpg

Intraocular Drug Delivery THAT LASTS

The first and only controlled release drug delivery platform for all cataract surgeons

HOW IT WORKS

The SpyGlass Pharma™ Drug Delivery Platform is implanted with the SpyGlass IOL into the capsular bag via standard cataract surgical technique

The SpyGlass Pharma™ Drug Delivery Platform has not been approved by the FDA

The SpyGlass Pharma™ Drug Delivery Platform consists of a single-piece, hydrophobic acrylic IOL and two drug eluting pads that slide over each haptic and securely attach at the haptic junction. With the drug pads securely attached, the IOL and pads are loaded into a standard IOL injector. The lens is advanced and injected through a sub 2.4 mm incision and implanted directly into the capsular bag. 

​

The drug pads remain outside the visual axis and continuously elute directly into the aqueous humor, which carries the active drug to targeted tissues. 

A VERSATILE SYSTEM

The SpyGlass Pharma™ Platform combines the heritage and performance of a single-piece IOL and the ability to secure innovative, drug-eluting pads to the haptics of the IOL prior to loading and implantation

Beyond bimatoprost, the SpyGlass Pharma™ drug-eluting pads are uniquely designed to deliver additional drugs to address multiple ophthalmic indications 

The SpyGlass Pharma™ Drug Delivery Platform has not been approved by the FDA

IOL_pads_outline.jpg

CONSISTENT DAILY RELEASE

DESIGNED FOR CONSISTENT DAILY RELEASE

Targeting three years of bimatoprost sustained delivery for glaucoma management

Spyglass_daily_release_3_years.jpg

The SpyGlass Pharma™ Drug Delivery Platform has not been approved by the FDA

PRECLINICAL TESTING

Compelling IOP lowering in normotensive beagles

  • 3 doses compared to 0.03% topical bimatoprost

  • Normalized out the IOP reduction from cataract surgery alone

​

Clear indication of safety in NZW rabbits

  • No detectable systemic exposure

  • No drug related AEs even at 10x max dose up to 9 months

FIH FEASIBILITY STUDY

A prospective study outside of the US to evaluate the safety and efficacy of the sustained release bimatoprost implant with SpyGlass IOL in patients with ocular hypertension or mild to moderate open-angle glaucoma

Spyglass_study_method.jpg

The SpyGlass Pharma™ Drug Delivery Platform has not been approved by FDA

FIH Feasibility Study
Subjects on 103 IOP lowering medication with cataracts
Washed out followed by surgery and SpyGlass Platform implantation

18 month data.png

​Results at 18 Months

​

  • 43.7% mean IOP reduction
    across all doses

     

  • All patients off topical
    IOP-lowering therapy

     

  • BCDVA 20/30 or better

bottom of page